Delayed treatment with the anti-inflammatory PPAR-γ agonist pioglitazone, but not the CB2R agonist AM1241, reduced IBA1 expression in the stroke cortex and improved neurological function while pretreatment with AM1241 reduced brain damages. This evidence concerns the gene PPARG and Stroke.